GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (OCSE:GMAB) » Definitions » PE Ratio

Genmab AS (OCSE:GMAB) PE Ratio : 21.24 (As of Dec. 12, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Genmab AS PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-12-12), Genmab AS's share price is kr1536.00. Genmab AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was kr72.31. Therefore, Genmab AS's PE Ratio for today is 21.24.

Good Sign:

Genmab AS stock PE Ratio (=21.24) is close to 10-year low of 19.21

During the past 13 years, Genmab AS's highest PE Ratio was 140.54. The lowest was 19.21. And the median was 54.19.

Genmab AS's EPS (Diluted) for the three months ended in Sep. 2024 was kr19.81. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was kr72.31.

As of today (2024-12-12), Genmab AS's share price is kr1536.00. Genmab AS's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was kr81.74. Therefore, Genmab AS's PE Ratio without NRI ratio for today is 18.79.

During the past 13 years, Genmab AS's highest PE Ratio without NRI was 140.54. The lowest was 17.74. And the median was 59.40.

Genmab AS's EPS without NRI for the three months ended in Sep. 2024 was kr26.08. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was kr81.74.

During the past 12 months, Genmab AS's average EPS without NRI Growth Rate was -6.10% per year. During the past 3 years, the average EPS without NRI Growth Rate was -2.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 25.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 38.50% per year.

During the past 13 years, Genmab AS's highest 3-Year average EPS without NRI Growth Rate was 119.20% per year. The lowest was -13.30% per year. And the median was 19.80% per year.

Genmab AS's EPS (Basic) for the three months ended in Sep. 2024 was kr19.94. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was kr72.84.

Back to Basics: PE Ratio


Genmab AS PE Ratio Historical Data

The historical data trend for Genmab AS's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS PE Ratio Chart

Genmab AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.54 34.11 58.74 35.61 32.64

Genmab AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.70 32.64 25.10 20.67 22.40

Competitive Comparison of Genmab AS's PE Ratio

For the Biotechnology subindustry, Genmab AS's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's PE Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's PE Ratio falls into.



Genmab AS PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Genmab AS's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=1536.00/72.310
=21.24

Genmab AS's Share Price of today is kr1536.00.
Genmab AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr72.31.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Genmab AS  (OCSE:GMAB) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Genmab AS PE Ratio Related Terms

Thank you for viewing the detailed overview of Genmab AS's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.